Inflammation and ankylosis: Still an enigmatic relationship in spondyloarthritis

Annals of the Rheumatic Diseases

Volumn 71, Issue 3, 2012, Pages 317-318

  Lories, Rik J U ^a   Dougados, Maxime ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Université Paris Descartes ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTHRITIS; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG TARGETING; EARLY DIAGNOSIS; EDITORIAL; GENETIC TRAIT; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SPONDYLOARTHRITIS; SYMPTOM;

FEMALE; HUMANS; MALE; OSSIFICATION, HETEROTOPIC; SPINE; SPONDYLITIS, ANKYLOSING;

EID: 84857198386     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200842     Document Type: Editorial

References (32)

1. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377:2127-37.
2. Stockdale J, Goodacre L. 'It's magic stuff': the experiences of patients with ankylosing spondylitis taking anti-TNF-alpha medication. Musculoskeletal Care 2009;7:162-77.
3. Keat AC, Gaffney K, Gilbert AK, et al. Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology (Oxford) 2008;47:481-3.
4. Braun J, Kalden JR. Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(4 Suppl 55):S164-7.
5. van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
6. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31. (Pubitemid 351705922)
7. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
8. Schett G, Coates LC, Ash ZR, et al. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 2011;13(Suppl 1):S4.
9. Sieper J, Appel H, Braun J, et al. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008;58:649-56. (Pubitemid 351364862)
10. Maksymowych WP. Disease modification in ankylosing spondylitis. Nat Rev Rheumatol 2010;6:75-81.
11. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 2009;11:221.
12. van der Heijde D, Machado P, Braun J et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multi-level analysis in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:369-73.
13. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93-102.
14. Pedersen SJ, Chiowchanwisawakit P, Lambert RG, et al. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol 2011;38:1349-54.
15. Chiowchanwisawakit P, Lambert RG, Conner- Spady B, et al. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 2011;63:2215-25.
16. Maksymowych WP. Progress in spondylarthritis. Spondyloarthritis: lessons from imaging. Arthritis Res Ther 2009;11:222.
17. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9. (Pubitemid 40814665)
18. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
19. Lories RJ, Derese I, de Bari C, et al. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007;56:489-97.
20. Lories RJ, Derese I, Luyten FP. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis. Rheumatology (Oxford) 2008;47:605-8. (Pubitemid 351619197)
21. Schett G, Stolina M, Dwyer D, et al. Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum 2009;60:2644-54.
22. Daoussis D, Liossis SN, Solomou EE, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010;62:150-8.
23. Wanders A, Heijde D, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65. (Pubitemid 40852884)
24. Baraliakos X, Listing J, von der Recke A, et al. The natural course of radiographic progression in ankylosing spondylitis-evidence for major individual variations in a large proportion of patients. J Rheumatol 2009;36:997-1002.
25. Baraliakos X, Listing J, von der Recke A, et al. The natural course of radiographic progression in ankylosing spondylitis: differences between genders and appearance of characteristic radiographic features. Curr Rheumatol Rep 2011;13:383-7.
26. Thomas GP, Brown MA. Genomics of ankylosing spondylitis. Discov Med 2010;10:263-71.
27. Masi AT, Walsh EG. Ankylosing spondylitis: integrated clinical and physiological perspectives. Clin Exp Rheumatol 2003;21:1-8. (Pubitemid 36267525)
28. Rudwaleit M, Landewé R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009;68:770-6.
29. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68 (Suppl 2):ii1-44.
30. Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:1369-74.
31. Dougados M, d'Agostino MA, Benessiano J, et al. The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine 2011;78:598-603.
32. Heuft-Dorenbosch L, Landewé R, Weijers R, et al. Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Ann Rheum Dis 2006;65:804-8. (Pubitemid 43799182)